Kalshi and AppliedXL have launched a pilot prediction market program to test contracts tied to FDA drug decisions and clinical trial outcomes. Operating within Kalshi’s CFTC‑regulated exchange, the initiative aims to improve transparency in drug development forecasts while safeguarding patient welfare and regulatory integrity.
Written By: Kirti Kumbhar,
M.Pharm (Quality Assurance)
Reviewed By: Pharmacally Editorial Team
Kalshi and AppliedXL have initiated a pilot partnership to evaluate whether regulated prediction markets can provide a transparent, publicly visible measure of expectations surrounding selected clinical trial outcomes and U.S. Food and Drug Administration (FDA) drug decisions. The initiative combines market‑based forecasting with structured analysis of publicly available evidence while maintaining clear separation between market activity and regulatory decision‑making.
Regulatory Framework and Independence
The pilot operates within Kalshi’s existing CFTC‑regulated exchange framework. FDA decisions remain entirely independent of these markets and continue to be governed solely by the agency’s established scientific and regulatory review process.
Market Structure and Resolution
Kalshi will list, operate, and settle contracts tied to objectively verifiable clinical and regulatory events. AppliedXL acts as an independent resolution‑analysis partner, evaluating candidate markets and providing advisory recommendations, while Kalshi alone determines which contracts are listed. Each contract asks a clearly defined question—such as whether the FDA will approve a specified drug by a particular date—and establishes resolution sources before trading begins. Contract prices reflect collective expectations of market participants; for example, a contract trading at $0.72 implies a 72% probability of the event occurring based on current market activity. These prices are not clinical assessments or medical advice.
AppliedXL provides independent resolution analysis, while Kalshi retains sole authority for all listing and settlement decisions. This distinction is central to the governance framework.
Addressing Public Data Gaps
Forecasts on drug development are routinely generated by analysts and investors, but many remain private. Public records can also be incomplete. An FDA analysis published in April 2026 found that 29.6% of studies considered highly likely to be subject to mandatory ClinicalTrials.gov reporting requirements had not submitted results, underscoring gaps in accessible data. The pilot will test whether prediction markets can complement scientific evidence by making collective expectations more transparent rather than replacing regulatory or clinical judgment.
Safeguards for Market Integrity
Not every milestone will qualify for a prediction market. AppliedXL reviews candidate events for objective verifiability, ethical considerations, patient recruitment status, and risks of material nonpublic information. Trials that have completed enrollment are prioritized to avoid influencing participation. AppliedXL employees are prohibited from trading in supported markets, and Kalshi enforces restrictions against participants with privileged access to confidential information. Employment verification, surveillance tools, and enforcement procedures are designed to mitigate insider trading risks.
Human Review in Resolution
AppliedXL continuously monitors public sources identified in each contract, organizes relevant documents, and compares new information against predefined resolution criteria. Human reviewers verify evidence, document rationale, and escalate ambiguous cases for further review. AppliedXL then submits its analysis to Kalshi, which independently evaluates the findings and makes the final settlement decision under exchange rules. This documented process allows corrections if authoritative public records change after publication.
Future Outlook
Kalshi Chief Executive Officer Tarek Mansour said the pilot will test whether carefully structured prediction markets can improve transparency around drug development while maintaining compliance and integrity standards.
AppliedXL Chief Executive Officer Francesco Marconi emphasized that reliable resolution requires documented evidence, human review, and predefined criteria rather than automated interpretation alone.
The companies said they expect to refine the framework as the pilot evolves. If successful, the initiative could establish prediction markets as a complementary indicator of expectations in drug development without influencing the scientific or regulatory decisions that ultimately determine a medicine’s future.
Reference
AppliedXL Partners with Kalshi on Resolution for Biopharma Prediction Markets — AppliedXL
About the Writer
Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements